Navigation Links
Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates
Date:7/2/2008

But the case isn't closed, American cardiologists say

WEDNESDAY, July 2 (HealthDay News) -- Injecting the artery-constricting hormone vasopressin in addition to adrenaline did not improve survival among people who had sudden cardiac arrest in an European trial, but American cardiologists said the finding does not rule out use of that treatment in some cases.

The report comes from a group, primarily French, that several years ago described promising results of combining vasopressin and epinephrine -- the formal name of adrenaline -- as part of the emergency treatment of cardiac arrest. The American Heart Association responded to that report in guidelines saying that a first shot of vasopressin might be substituted for adrenaline, the traditional drug for cardiac arrest, in some cases.

But the latest report, on a total of nearly 3,000 people, found that "the combination of vasopressin and epinephrine during advanced cardiac life support for out-of-hospital cardiac arrest does not improve outcome." The study was published in the July 3 issue of the New England Journal of Medicine.

In each group, about one in five of those treated survived long enough to be admitted to a hospital -- 20.7 percent of the combined therapy group, 21.3 percent of the adrenaline-only group. The one-year survival rate was 1.3 percent for those given the two drugs, 2.1 percent of those given only adrenaline.

The reason for not giving up entirely on vasopressin is due to the average response time in the French study, said Dr. Joseph P. Ornato, chairman of emergency medicine at Virginia Commonwealth University, and a member of the committee that drew up the heart association guidelines.

"Paris is a city with a lot of traffic," Ornato said. "If you look at the time of collapse to the time of treatment, the first crew was at the scene in an average of 7.2 minutes. They didn't start to treat until 16.3 minutes. The first steady drug injection was not until 21 minutes."

That interval means everything, because "we lose roughly 10 percent of the odds of the resuscitation every minute," Ornato said.

In Richmond, "90 percent of the time, we respond within eight minutes or less," he said.

And so, Ornato said, "I am less than convinced that this completely answers the question, because I don't know what it means when your drugs don't start until 20 minutes after the heart has stopped."

The trial "raises as many questions as it answers," said Dr. Nisha Chandra-Strobos, chief of cardiology at the Bayview division of Johns Hopkins University.

The slow response time is one major reason, she said: "A time to injection of 21 minutes, the game is really over at that time."

The heart association guidelines which Ornato helped prepare apply only to the medical personnel called for emergency treatment of cardiac arrest. The heart association advises persons without medical training to call for that help as quickly as possible by dialing 911.

Emergency measures can be taken before medical help arrives. Newly updated advice by the heart association says that simply depressing the chest periodically and continually can contribute to survival. If the cardiac arrest occurs in a public place such as an airport, a portable defibrillator may be available. It should be placed against the chest to deliver an electric shock that might start the heart beating again.

More information

The symptoms of cardiac arrest and what to do about them are described by the American Heart Association.



SOURCES: Joseph P. Ornato, M.D., chairman, emergency medicine, Virginia Commonwealth University, Richmond, Va.; Nisha Chandra-Strobos, M.D., chief, cardiology, Johns Hopkins Bayview, Baltimore; July 3, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Two-Drug Combo Reduces Diabetic Kidney Damage
2. Two-Drug Combo Fights Brain Tumors
3. Glaucoma Treatment Can Prevent Blindness
4. TomoTherapy Concludes Treatment Quality Challenge
5. Best treatment for MS may depend on disease subtype
6. Expanded Seconds-Count.org Helps Physicians Navigate Spectrum of Cardiovascular Disease Treatment Options
7. ReachMD XM 157 Announces Medical Information Feature on Irritable Bowel Syndrome, Its Treatments, and the Role of Probiotics
8. OptiNose presents data on highly effective migraine treatment
9. Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
10. Treatment for Cigarette, Alcohol & Drug Use During Pregnancy Dramatically Improves Outcomes for Mom and Baby, Kaiser Permanente Study Shows
11. Rheumatoid Arthritis Treatment Guidelines Updated
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
(Date:5/31/2016)... ... ... Interest is on the rise for using the CRISPR-Cas9 system for functional ... hit validation. A key reason may be that high-throughput synthesis—combined with a proprietary algorithm ... collections in arrayed formats. , Arrayed crRNA screens have the advantage ...
(Date:5/31/2016)... ... May 31, 2016 , ... MinerEye ... Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each year, Gartner ... research reports evaluating these innovative vendors and their products and services. , According ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... media enterprise focused on patients with cancer, has added Cancer and Careers ... website visitors with more timely content on continuing successful careers while fighting cancer. ...
(Date:5/30/2016)... Salt Lake City, Utah (PRWEB) , ... May ... ... health insurance reimbursement for small businesses, announced today the publication of an original ... helps business owners and health insurance professionals understand how Zane Benefits complies with ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 LabStyle ... Dario™ Diabetes Management Tool, today announced that the Company,s Chief ... Marcum MicroCap Conference being held June 1-2 in ... being held June 7-9 in Los Angeles, CA. ... discuss recent corporate and operational milestones, including the U.S. FDA ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
Breaking Medicine Technology: